A. Lluch
Cancer Research · 2005–2016
A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Cancer Research — 87 citations into it
Whom A. Lluch trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Charles M. Perou (in Cancer Research)
Papers from A. Lluch's perspective
Ordered by how strongly the researchers A. Lluch trusts endorse each paper. Same corpus, a different order for every researcher.
- Molecular portraits of human breast tumours (Nature)
- Repeated observation of breast tumor subtypes in independent gene expression data sets (Proceedings of the National Academy of Sciences of the United States of America)
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (Proceedings of the National Academy of Sciences of the United States of America)
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (Clinical Cancer Research)
- The PIK3CA gene is mutated with high frequency in human breast cancers (Cancer Biology & Therapy)
- A gene-expression signature as a predictor of survival in breast cancer. (New England Journal of Medicine)
- Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (Genome Biology)
- PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. (Cancer Research)
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (Cancer Cell)
- Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data
Their papers
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer (2008) — 1,067 citations
- High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. (2012) — 139 citations
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. (2016) — 787 citations
- Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012) — 625 citations
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. (2012) — 2,018 citations
- GENOMIC PREDICTOR OF RESPONSE AND SURVIVAL FOLLOWING TAXANE-ANTHRACYCLINE CHEMOTHERAPY FOR INVASIVE BREAST CANCER (2011) — 630 citations
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. (2010) — 1,220 citations
- Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009) — 863 citations
- Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. (2005) — 1,589 citations